{"filings":[{"id":3355036,"accession_number":"0001193125-26-418417","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K/A","filed_at":"2026-10-09T10:17:57+00:00","items":["8.01"],"status":"ready","headline":"Atrium Therapeutics corrects post-PIPE share count to 21,571,507, including make-whole spin-off shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE securities purchase agreement dated Oct. 7, 2026 with accredited investors covers 5,170,384 common shares plus pre-funded warrants for up to 1,134,930 shares.","Amendment No. 1 restates shares outstanding after the offering as 21,571,507, correcting the number in the original Oct. 8, 2026 Form 8-K; no other information revised.","That total includes shares issued to settle make-whole equity awards granted in connection with the Company's spin-off from Avidity Biosciences, Inc.","Closing of the offering remains subject to conditions; the company flags risk that it or the PIPE Investors may fail to satisfy them.","Amendment signed Oct. 9, 2026 by Chief Executive Officer Kathleen Gallagher."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3328037,"accession_number":"0001193125-26-417402","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-10-08T10:52:04+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Atrium Therapeutics raises $50M PIPE at $7.93/share, extending cash runway through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE priced at-the-market: 5,170,384 shares at $7.93 plus pre-funded warrants for 1,134,930 shares at $7.929 each (exercise price $0.001); gross proceeds ~$50M.","Investors include Sirenia Capital Management, Aberdeen Investments, Montanova, Sessa Capital and Casdin Capital; Leerink Partners is lead placement agent with Cantor, Barclays and Wells Fargo.","Net proceeds fund development of its two lead precision-cardiology RNA product candidates, other research programs, working capital and general corporate purposes.","Company estimates proceeds plus existing cash fund operations through 2028; closing expected on or about October 9, 2026.","Post-offering common shares outstanding total 22,276,027, including shares issued to settle make-whole equity awards from the Avidity Biosciences spin-off."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2245716,"accession_number":"0001193125-26-349482","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-08-13T20:50:28+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atrium Therapeutics Q2 2026: IND cleared for ATR 1072, BMS milestone $15M, cash $263.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA cleared IND for ATR 1072; Corventis Phase 1/2 trial in PRKAG2 syndrome launched, ~37 participants planned.","Earned second BMS milestone payment of $15M in August, to be recognized in Q3 2026.","Q2 2026 collaboration revenue $3.0M; R&D expenses $15.3M; G&A $10.3M.","Cash, equivalents and short-term investments $263.9M as of June 30, 2026; runway through mid-2028.","Expect first Corventis participant enrollment by end of 2026; initial data 2H 2027; IND for ATR 1086 in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1639476,"accession_number":"0001193125-26-303393","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-07-14T21:14:28+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atrium Therapeutics receives FDA IND clearance for ATR 1072 in PRKAG2 syndrome; Phase 1/2 trial to start","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for ATR 1072, a precision cardiology RNA therapeutic for PRKAG2 syndrome.","Corventis Phase 1/2 trial will enroll ~37 participants; first patient expected by end of 2026.","Initial proof-of-concept data anticipated in second half of 2027.","PRKAG2 syndrome is a rare genetic cardiomyopathy with no approved therapy addressing root cause.","This is Atrium's first precision cardiology program to enter clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":444276,"accession_number":"0001193125-26-224238","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-05-14T20:50:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atrium Therapeutics reports Q1 collaboration revenue $19.6M, driven by $15M BMS milestone; cash $267.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $19.6M in Q1 2026, primarily a $15M milestone from BMS partnership.","R&D expenses $16.7M, G&A $20.3M; cash and equivalents $267.8M.","ATR 1072 IND submission planned for H2 2026; pre-IND discussions with FDA/Health Canada completed.","Company launched as independent public on Feb 27, 2026 after spin-off from Avidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112737,"accession_number":"0001193125-26-083227","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","5.01","5.02","9.01"],"status":"ready","headline":"Atrium Therapeutics completes spin-off from Avidity; begins trading under RNA on Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Separation of Atrium Therapeutics (SpinCo) from Avidity effective Feb 26, 2026; one SpinCo share for every ten Avidity shares distributed.","Amended License Agreement expands IP cross-licenses; Transition Services Agreement provides support services from Avidity.","Board elected: Carsten Boess, W. Michael Flanagan, Simona Skerjanec, Troy Wilson; terms expire at first/second annual meetings.","Executive officers: Kathleen Gallagher (CEO) and Brendan Winslow (CFO); employment agreements and compensatory plans adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112736,"accession_number":"0001193125-26-077105","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Atrium Therapeutics completes spin-off from Avidity; 15.5M shares distributed, trading begins Feb 27 under RNA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Avidity distributed 15,514,966 Atrium shares at a ratio of 1 share per 10 Avidity shares; holds no equity interest after.","Atrium shares expected to begin trading on Nasdaq under symbol RNA on February 27, 2026.","Registration statement declared effective and spin-off consummated on February 26, 2026.","Novartis acquisition of Avidity expected to close on February 27, 2026, subject to conditions.","Atrium focused on early-stage precision cardiology programs ATR-1086 (phospholamban) and ATR-1072 (PRKAG2 syndrome)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}